Switch theme
Sign up to access all valuation multiples
Hubei Jumpcan Pharmaceutical Co Ltd engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemicals based on Chinese traditional medicines, and Chinese medicine health products in China. It offers Chinese and Western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, and geriatric. The company also develops Chinese and western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.
1997
5.2K+
LTM Revenue $1.1B
Last FY EBITDA $462M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hubei Jumpcan has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Hubei Jumpcan achieved revenue of $1.1B and an EBITDA of $462M.
Hubei Jumpcan expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hubei Jumpcan valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $866M | XXX | $887M | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $462M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 41% | XXX | XXX | XXX |
| EBIT | $372M | XXX | $338M | XXX | XXX | XXX |
| EBIT Margin | 34% | XXX | 30% | XXX | XXX | XXX |
| Net Profit | $334M | XXX | $353M | XXX | XXX | XXX |
| Net Margin | 31% | XXX | 32% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Hubei Jumpcan's stock price is CNY 26 (or $4).
Hubei Jumpcan has current market cap of CNY 24.3B (or $3.4B), and EV of CNY 12.3B (or $1.7B).
See Hubei Jumpcan trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $3.4B | XXX | XXX | XXX | XXX | $0.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Hubei Jumpcan has market cap of $3.4B and EV of $1.7B.
Hubei Jumpcan's trades at 1.5x EV/Revenue multiple, and 3.7x EV/EBITDA.
Equity research analysts estimate Hubei Jumpcan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hubei Jumpcan has a P/E ratio of 10.1x.
See valuation multiples for Hubei Jumpcan and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.4B | XXX | $3.4B | XXX | XXX | XXX |
| EV (current) | $1.7B | XXX | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBIT | 4.6x | XXX | 5.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.1x | XXX | 9.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 6.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHubei Jumpcan's last 12 month revenue growth is 1%
Hubei Jumpcan's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Hubei Jumpcan's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hubei Jumpcan's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hubei Jumpcan and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 41% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 39% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hubei Jumpcan acquired XXX companies to date.
Last acquisition by Hubei Jumpcan was XXXXXXXX, XXXXX XXXXX XXXXXX . Hubei Jumpcan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hubei Jumpcan founded? | Hubei Jumpcan was founded in 1997. |
| Where is Hubei Jumpcan headquartered? | Hubei Jumpcan is headquartered in China. |
| How many employees does Hubei Jumpcan have? | As of today, Hubei Jumpcan has 5.2K+ employees. |
| Is Hubei Jumpcan publicy listed? | Yes, Hubei Jumpcan is a public company listed on SHG. |
| What is the stock symbol of Hubei Jumpcan? | Hubei Jumpcan trades under 600566 ticker. |
| When did Hubei Jumpcan go public? | Hubei Jumpcan went public in 2001. |
| Who are competitors of Hubei Jumpcan? | Similar companies to Hubei Jumpcan include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Hubei Jumpcan? | Hubei Jumpcan's current market cap is $3.4B |
| What is the current revenue of Hubei Jumpcan? | Hubei Jumpcan's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Hubei Jumpcan? | Hubei Jumpcan revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of Hubei Jumpcan? | Current revenue multiple of Hubei Jumpcan is 1.6x. |
| Is Hubei Jumpcan profitable? | Yes, Hubei Jumpcan is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
